Find Funding Opportunities

The purpose of this notice is to inform applicants of an informational webinar for RFA-NS-24-029 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)".

The purpose of this notice is to inform applications of NINDS' IC-specific information for PAR-22-105 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) and PAR-22-109 Dissemination and Implementation Research in Health (R21 Clinical Trial Optional).

The purpose of this notice is to inform applications of NINDS' IC-specific information for PAR-22-106 Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed).

This notice is provided to inform the public that the final receipt date for PAR-23-142 NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required) and PAR-23-143 NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed) will be February 12, 2024. NINDS will not reissue these notices of funding opportunity (NOFOs). NINDS will continue to utilize the F32 and K99/R00 mechanisms specifically intended to support postdoctoral fellows.

This is a request for information to gather ideas and commentary on the potential development and program planning of hubs or centers for testing sensor performance. Responses will be examined for enthusiasm and general support for the creation of several hubs for testing sensors that are developed by not only NIH awardees, but the broader engineering community.

The purpose of this notice is to correct the expiration date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)".

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

This Notice encourages eligible awardees in the BRAIN Initiative community to apply for administrative supplements in response to PA-23-189, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031) and encourages institutions to prioritize inclusion by supporting the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.

Excellent mentorship and superior training are critical to the development of exceptional future scientists. To recognize the crucial role great mentors play in the development of future leaders in neuroscience, the National Institute of Neurological Disorders and Stroke (NINDS) created the Landis Award for Outstanding Mentorship. Each year, this award provides $100,000.00 (direct costs) to up to five (5) faculty members, who have demonstrated a dedication to outstanding mentorship and training. This funding is intended to help foster the research career development of current or additional students and post-doctorates under the guidance of outstanding mentors. NINDS hopes that this tangible award will impress upon the scientific community as a whole, and faculty and institutional leaders in particular, the high value NINDS places on outstanding training and mentorship. Further, NINDS hopes that it encourages institutions to reward individuals not only for outstanding research accomplishments but also for their impact on the lives of others, and the future of neuroscience, through outstanding mentorship and training.